INTEGRATED BIOPHARMA INC (INBP)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 06-30. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue Annual

0 25M 50M 75M FY12: 36.6M FY13: 33.6M FY14: 33.7M FY15: 37.5M FY16: 42.2M FY17: 47M FY18: 43.7M FY19: 50M FY20: 52.8M FY21: 63.6M FY22: 56.2M FY23: 50.7M FY24: 50.3M FY25: 54.4M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Gross Profit Annual

0 3.5M 7M 10.5M FY11: 10.2M FY12: 7.6M FY13: 5.5M FY14: 4.9M FY15: 4.4M FY16: 5.5M FY17: 6.7M FY18: 5M FY19: 6.2M FY20: 6.7M FY21: 9.5M FY22: 6.6M FY23: 4.1M FY24: 3.9M FY25: 5.6M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating Income Annual

-2M 0 2M 4M 6M FY11: -362K FY12: -506K FY13: 1.1M FY14: 1.4M FY15: 933K FY16: 2.1M FY17: 3.2M FY18: 1.7M FY19: 2.7M FY20: 3.3M FY21: 5.8M FY22: 2.7M FY23: 120K FY24: 251K FY25: 2M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Net Income Annual

-3M 0 3M 6M 9M FY11: -2.3M FY12: -2.7M FY13: 93K FY14: 131K FY15: 735K FY16: 958K FY17: 2.3M FY18: 679K FY19: 1.7M FY20: 4.1M FY21: 8M FY22: 3.8M FY23: -34K FY24: 112K FY25: 808K FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Cost of Revenue Annual

0 20M 40M 60M FY17: 40.3M FY18: 38.7M FY19: 43.8M FY20: 46M FY21: 54.1M FY22: 49.7M FY23: 46.6M FY24: 46.4M FY25: 48.8M FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25

Operating Cash Flow Annual

-1.5M 0 1.5M 3M 4.5M FY11: 392K FY12: -771K FY13: -1.4M FY14: 1.9M FY15: -113K FY16: -594K FY17: 397K FY18: 1.2M FY19: 328K FY20: 1.3M FY21: 3M FY22: 4.1M FY23: 1.2M FY24: 943K FY25: 2.1M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Free Cash Flow Annual

-1.5M 0 1.5M 3M 4.5M FY11: 91K FY12: -926K FY13: -1.5M FY14: 1.7M FY15: -348K FY16: -703K FY17: 70K FY18: 921K FY19: -86K FY20: 1.1M FY21: 2.8M FY22: 3.6M FY23: 1.1M FY24: 390K FY25: 1.9M FY11 FY13 FY15 FY17 FY19 FY21 FY23 FY25

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 15M 30M 45M FY12: 21M FY13: 21.2M FY14: 21.2M FY15: 29.4M FY16: 21.2M FY17: 30.2M FY18: 30.3M FY19: 29.6M FY20: 31.2M FY21: 32.1M FY22: 32.3M FY23: 29.9M FY24: 30.9M FY25: 31.2M FY13 FY15 FY17 FY19 FY21 FY23 FY25

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.27 -0.18 -0.09 0.00 0.09 0.18 0.27 Q4 '11: -0.11 Q1 '12: -0.09 Q2 '12: -0.11 Q3 '12: -0.11 Q4 '12: -0.13 Q1 '13: -0.20 Q2 '13: -0.13 Q3 '13: -0.12 Q4 '13: 0.00 Q1 '14: 0.06 Q2 '14: 0.04 Q3 '14: 0.05 Q4 '14: 0.01 Q1 '15: 0.01 Q2 '15: 0.01 Q3 '15: 0.02 Q4 '15: 0.01 Q1 '16: 0.01 Q2 '16: 0.00 Q3 '16: 0.01 Q4 '16: 0.05 Q1 '17: 0.07 Q2 '17: 0.07 Q3 '17: 0.08 Q4 '17: 0.10 Q1 '18: 0.06 Q2 '18: 0.04 Q3 '18: 0.04 Q4 '18: 0.01 Q1 '19: 0.03 Q2 '19: 0.06 Q3 '19: 0.08 Q4 '19: 0.06 Q1 '20: 0.06 Q2 '20: 0.08 Q3 '20: 0.08 Q4 '20: 0.13 Q1 '21: 0.15 Q2 '21: 0.16 Q3 '21: 0.17 Q4 '21: 0.25 Q1 '22: 0.24 Q2 '22: 0.23 Q3 '22: 0.22 Q4 '22: 0.13 Q1 '23: 0.11 Q2 '24: -0.01 Q3 '24: 0.00 Q4 '24: 0.00 Q1 '25: 0.01 Q2 '25: 0.03 Q3 '25: 0.04 Q4 '25: 0.04 Q1 '26: 0.03 Q2 '26: -0.01 Q3 '26: -0.06 Q2 '13 Q1 '15 Q4 '16 Q3 '18 Q2 '20 Q1 '22 Q4 '24 Q3 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.